Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 10;11:628706. doi: 10.3389/fonc.2021.628706

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Yuan, Bao, Ma, Men, Wang and Hui

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Radar map of the Bayesian ranking results of 4 different endpoints. This map indicates the probability of each comparable treatment being ranked first in terms of different endpoints. Each vertex of the rhombus represents an endpoint, and each colored line represents a comparable treatment with the probability of being ranked first increasing from the inner to the outer rhombus. Neoadjuvant CRT had the greatest probability of being ranked first among these comparable treatments in terms of all the endpoints. The radar map is depicted according to the Bayesian ranking results based on SUCRA scores presented in supplement. CT, chemotherapy; RT, radiotherapy; CRT, chemoradiotherapy; OS, overall survival; PFS, progression-free survival; DFS, disease-free survival; TFD, reduction in treatment failure due to distant metastasis; TFL, reduction in treatment failure due to locoregional recurrence.